Dr. Mirko Buchholz received his PhD in Medicinal and Computational Chemistry from the Martin-Luther-University Halle-Wittenberg in 2007, and is now the CDO/CSO of PerioTrap Pharmaceuticals GmbH in Halle, Germany. He worked as PostDoc, Team Leader and Head of Computational Chemistry at Probiodrug AG, Halle (2007–2013). In 2013, he moved to Fraunhofer IZI-MWT and has worked as a group leader for Drug Design and Analytical Chemistry. He acted as a Co-Founder of PerioTrap (Spin-off of Fraunhofer IZI-MWT) in 2018, and since then he has been the CSO and CDO of the Company. From 2013 to 2021 he was a guest lecturer in Pharmaceutical Sciences at Leipzig University. His research topics mainly include the oral microbiome, its shift in disease, and possibilities to readjust it back into symbiosis.
Dr. Mirko Buchholz received his PhD in Medicinal and Computational Chemistry from the Martin-Luther-University Halle-Wittenberg in 2007, and is now the CDO/CSO of PerioTrap Pharmaceuticals GmbH in Halle, Germany. He worked as PostDoc, Team Leader and Head of Computational Chemistry at Probiodrug AG, Halle (2007–2013). In 2013, he moved to Fraunhofer IZI-MWT and has worked as a group leader for Drug Design and Analytical Chemistry. He acted as a Co-Founder of PerioTrap (Spin-off of Fraunhofer IZI-MWT) in 2018, and since then he has been the CSO and CDO of the Company. From 2013 to 2021 he was a guest lecturer in Pharmaceutical Sciences at Leipzig University. His research topics mainly include the oral microbiome, its shift in disease, and possibilities to readjust it back into symbiosis.